NEW YORK (TheStreet) -- Goldman Sachs upgraded NuVasive (NUVA) - Get Report to "buy" and set a $43 price target. The firm said discrete P&L items and natural operating leverage can drive EBIT margin expansion.
The stock closed at $34.82 on Wednesday.
Must Read: Warren Buffett's 25 Favorite Stocks
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.